Immune thrombocytopenic purpura

Results: 50



#Item
21Investigation of whether the acute hemolysis associated with Rho(D) immune globulin intravenous (human) administration for treatment of immune thrombocytopenic purpura is consistent with the acute hemolytic transfusion r

Investigation of whether the acute hemolysis associated with Rho(D) immune globulin intravenous (human) administration for treatment of immune thrombocytopenic purpura is consistent with the acute hemolytic transfusion r

Add to Reading List

Source URL: www.fda.gov.

Language: English
22Baxter Healthcare Corporation One Baxter Way Westlake Village, California[removed]3000 Cangene Corporation

Baxter Healthcare Corporation One Baxter Way Westlake Village, California[removed]3000 Cangene Corporation

Add to Reading List

Source URL: www.fda.gov

Language: English
23CSL Behring[removed]Draft Labeling Text 1 2

CSL Behring[removed]Draft Labeling Text 1 2

Add to Reading List

Source URL: www.fda.gov

Language: English
24® WinRho SDF INFORMATION FOR PATIENTS BEING TREATED FOR ITP You should read this leaflet carefully each time before you are scheduled to receive a

® WinRho SDF INFORMATION FOR PATIENTS BEING TREATED FOR ITP You should read this leaflet carefully each time before you are scheduled to receive a

Add to Reading List

Source URL: www.fda.gov

Language: English
25HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Rhophylac® safely and effectively. See full prescribing information for Rhophylac®. Rhophylac®

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Rhophylac® safely and effectively. See full prescribing information for Rhophylac®. Rhophylac®

Add to Reading List

Source URL: www.fda.gov

Language: English
26Rho(D) Immune Globulin Intravenous (Human) WinRho® SDF WARNING: INTRAVASCULAR HEMOLYSIS (IVH) Intravascular hemolysis (IVH) leading to death has been reported in patients treated for immune thrombocytopenic purpura (ITP

Rho(D) Immune Globulin Intravenous (Human) WinRho® SDF WARNING: INTRAVASCULAR HEMOLYSIS (IVH) Intravascular hemolysis (IVH) leading to death has been reported in patients treated for immune thrombocytopenic purpura (ITP

Add to Reading List

Source URL: www.fda.gov

Language: English
    27Critical Review The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports Deirdra R. Terrell,1* Laura A. Beebe,1 Sara K. Vesely,1 Barbara R. Neas,1 Jodi B. Segal,2 an

    Critical Review The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports Deirdra R. Terrell,1* Laura A. Beebe,1 Sara K. Vesely,1 Barbara R. Neas,1 Jodi B. Segal,2 an

    Add to Reading List

    Source URL: www.ouhsc.edu

    Language: English - Date: 2011-02-21 15:41:46
    28research paper Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials

    research paper Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials

    Add to Reading List

    Source URL: www.ouhsc.edu

    Language: English - Date: 2011-02-21 15:34:21
    29Initial management of immune thrombocytopenic purpura in children: Is supportive counseling without therapeutic intervention sufficient? In this issue of The Journal, Dickerhoff and von Ruecker1 describe their 7-year exp

    Initial management of immune thrombocytopenic purpura in children: Is supportive counseling without therapeutic intervention sufficient? In this issue of The Journal, Dickerhoff and von Ruecker1 describe their 7-year exp

    Add to Reading List

    Source URL: www.ouhsc.edu

    Language: English - Date: 2005-09-19 15:41:10
    30CLINICAL MANAGEMENT CONTROVERSIES The Child With Immune Thrombocytopenic Purpura: Is Pharmacotherapy or Watchful Waiting the Best Initial Management? A Panel Discussion From the 2002 Meeting of the American Society of

    CLINICAL MANAGEMENT CONTROVERSIES The Child With Immune Thrombocytopenic Purpura: Is Pharmacotherapy or Watchful Waiting the Best Initial Management? A Panel Discussion From the 2002 Meeting of the American Society of

    Add to Reading List

    Source URL: www.ouhsc.edu

    Language: English - Date: 2005-09-19 15:36:50